BURLINGTON, N.C.--(BUSINESS WIRE)--Esoterix Clinical Trials Services, a division of Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), today announced a strategic alliance with the David H. Murdock Research Institute (DHMRI) to provide its clients with access to enhanced assay development services. Assays developed at DHMRI for contracted research will be transferred to LabCorp Clinical Trials laboratories worldwide to support global clinical studies. The agreement also provides a mechanism for downstream commercialization of companion diagnostics and other biomarker assays once clinical validation has been established.
